Tabuk announced today that it had signed an exclusive agreement with Panpharma for the marketing and distribution of one of the world wide best-selling pharmaceutical hospital products for the MENA region. Under the terms of the agreement, Tabuk will oversea all necessary regulatory filings, and will be responsible for the marketing and sales of the product in the region.
Panpharma is an independent pharmaceutical company specialized in the aseptic filling of powders for injection, and the manufacturing of parenteral liquid forms. The company is based in Fougeres, France and began operations in 1981. Specializing in research, development and production of parenteral antibiotics, it was awarded by the European Health Council for making available high quality injectable medicines throughout Europe and Africa. By the year 2004, Panpharma was recognized as the top injectable pharmaceutical manufacturer in Europe. Panpharma has a large portfolio of essential branded generic drugs commercialized in 80 countries from Europe, Canada, Africa, Latin America, the Middle East and Asia.
”Tabuk is highly excited about the opportunities this agreement would present. With the proven pharmaceutical experience in the Injectables business, Tabuk is focused on growing this business through the launch of new products into the Middle East and North Africa Region, and by strengthening its sales and marketing network”, commented Mrs. Rana Azzam, Business development Director at Tabuk Pharmaceuticals.